Actively Recruiting

All Genders
ID03327779

World Bleeding Disorders Registry

Led by World Federation of Hemophilia · Updated on 2023-08-14

20000

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are conducting the World Bleeding Disorders Registry (WBDR), an international observational study focused on people diagnosed with Hemophilia A, Hemophilia B, and von Willebrand Disease. The registry aims to collect standardized, real-world patient data from treatment centers worldwide to better understand these bleeding disorders and inform clinical care. This global effort involves collaboration between the World Federation of Hemophilia, Karolinska Institute, and Health Solutions. The WBDR involves enrolling patients through more than 200 Hemophilia Treatment Centres across over 50 countries. Participating centers must have reliable internet access and resources to enter and maintain patient data over time. The registry collects anonymous information about the disease type, severity, symptoms, and treatments experienced by patients. This study is ongoing and plans to follow patients long-term to gather comprehensive data from diverse healthcare settings. Participants contribute data through their treatment centers, which input information into the registry platform. Researchers track key outcomes such as the number of patients registered, the number of participating centers, and countries involved over five years. This large-scale data collection helps address scientific and clinical questions about bleeding disorders globally. Participation does not involve treatment changes but supports advancing knowledge through observation and data sharing.

CONDITIONS

Brief Title

World Bleeding Disorders Registry

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients of participating Hemophilia Treatment Centres with Hemophilia A or B, or von Willebrand Disease
Not Eligible

You will not qualify if you...

  • none

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person or virtual)

Long-term Monitoring

Duration - Up to 5 years

Participants with hemophilia or von Willebrand Disease are observed over time to collect real world data on their clinical experience.

Regular visits depending on treatment center schedules

Trial Site Locations

Total: 1 location

1

World Federation of Hemophilia

Montreal, Quebec, Canada, H3G 1T7

Actively Recruiting

Loading map...

Research Team

D

Donna Coffin, M.Sc.

E

Emily Ayoub, Ph.D.

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

A Multicenter, Randomized, Open-Label Phase III Trial Evalua...

Hemophilia A

Actively Recruiting

8 locations

A Multicenter, Randomized, Open-Label Phase III Trial Evalua...

Hemophilia A

Actively Recruiting

2 locations

An Open-Label Study of Marstacimab Prophylaxis Compared to H...

Hemophilia A

Actively Recruiting

34 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here